Alpha 2.0
Login Register
» Articles » PMID: 34058144

Papilledema and Hypervitaminosis A After Elexacaftor/tezacaftor/ivacaftor for Cystic Fibrosis

Overview
Journal Can J Ophthalmol
Publisher Elsevier
Specialty Ophthalmology
Date 2021 May 31
PMID 34058144
Citations 7
Authors
Matthew J Miller
Rod Foroozan
Affiliations
Soon will be listed here.
Citing Articles

Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight.

Fabricius D, Knieling T, Zurmuehl N, Makedon L, Freihorst J, Schmidt H Mol Cell Pediatr. 2024; 11(1):4.

PMID: 38717689 PMC: 11078909. DOI: 10.1186/s40348-024-00178-6.

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis.

Hergenroeder G, Faino A, Bridges G, Bartlett L, Cogen J, Green N J Cyst Fibros. 2023; 22(6):1048-1053.

PMID: 37563007 PMC: 10843772. DOI: 10.1016/j.jcf.2023.08.002.

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.

Olivier M, Kavvalou A, Welsner M, Hirtz R, Strassburg S, Sutharsan S Front Pharmacol. 2023; 14:1176815.

PMID: 37229253 PMC: 10203630. DOI: 10.3389/fphar.2023.1176815.

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.

Tummler B Front Pharmacol. 2023; 14:1158207.

PMID: 37025483 PMC: 10072268. DOI: 10.3389/fphar.2023.1158207.

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.

Kapouni N, Moustaki M, Douros K, Loukou I Children (Basel). 2023; 10(3).

PMID: 36980112 PMC: 10047761. DOI: 10.3390/children10030554.